시장보고서

상품코드

1819995

급성 골수성 백혈병(AML) 치료 시장 보고서 : 치료 유형별, 약물 유형별, 투여 경로별, 지역별(2025-2033년)

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033

발행일: 2025년 09월 | 리서치사:

IMARC | 페이지 정보: 영문 137 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 급성 골수성 백혈병(AML) 치료제 시장 규모는 2024년 13억 4,360만 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 34억 6,140만 달러에 달할 것으로 예상하며, 2025년부터 2033년까지 10.53%의 연평균 성장률(CAGR)을 기록할 것으로 전망하고 있습니다.

급성 골수성 백혈병(AML)은 비정상 세포가 빠르게 증식하는 클론성 악성 종양입니다. 주로 골수와 백혈구(WBC)에 영향을 미치며, 피부 변색, 호흡곤란, 피로감, 고열, 체중 감소, 잇몸 출혈, 코피가 특징입니다. 일반적으로 사용되는 AML 치료에는 화학요법, 면역요법, 분자표적치료, 호르몬요법, 수술 등이 있습니다. 이러한 치료는 일반적으로 효과를 높이고 합병증을 최소화하며 신체의 면역 체계를 강화하기 위해 줄기세포 이식과 함께 사용됩니다.

전 세계적으로 백혈병의 유병률이 증가하고 있는 것은 시장 성장을 촉진하는 중요한 요인 중 하나입니다. 또한, 이러한 질병에 걸리기 쉬운 노년층 인구가 증가하고 있는 것도 시장 성장을 촉진하고 있습니다. AML은 주로 체내 유전자 돌연변이에 의해 발생하며, 혈구 생산량에 영향을 미칩니다. 이에 따라 병용요법 및 표적 치료제가 널리 채택되고, 암 치료에 사용할 수 있는 대체요법에 대한 인식이 높아진 것도 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한, 개량된 면역독소, 알킬화제, 단클론항체, 다제내성 조절제의 등장도 성장을 촉진하는 큰 요인입니다. 이러한 치료제는 치료 효과의 장기화, 더 높은 효능, 백혈병 세포의 조기 및 정확한 식별, 암 재발 가능성 감소를 가져옵니다. 종양학 분야의 광범위한 연구개발(R&D) 활동과 기존 의료 인프라의 대폭적인 개선 등 다른 요인들도 시장을 더욱 견인할 것으로 예상됩니다.

본 보고서에서 다루는 주요 질문

세계 급성 골수성 백혈병(AML) 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 변화할 것인가?
COVID-19가 세계 급성 골수성 백혈병(AML) 치료제 시장에 미치는 영향은?
주요 지역 시장이란?
치료 유형별 시장 분석은?
약제 종류별 시장 현황은?
투여 경로에 따른 시장 분석은?
산업 가치사슬의 다양한 단계는 무엇인가?
업계의 주요 촉진요인과 과제는 무엇인가?
세계 급성 골수성 백혈병(AML) 치료제 시장의 구조와 주요 플레이어는?
업계 경쟁은 어느 정도인가?

Acute myeloid leukemia (AML) refers to a clonal malignancy leading to the rapid growth of abnormal cells. It primarily impacts the bone marrow and white blood cells (WBCs) and is characterized by the discoloration of skin, breathlessness, fatigue, high body temperatures, weight loss, bleeding gums and nosebleeds. Some of the commonly used AML therapies include chemo-, immuno-, targeted- and hormonal therapies and surgical procedures. These therapeutics are usually combined with stem cell transplants to increase the efficacy, minimize complications and strengthen the immune system of the body.

The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth. AML is primarily caused by genetic mutations in the body that impacts the levels of blood cell production. In line with this, the widespread adoption of combination and targeted therapies and increasing awareness regarding the available alternatives for cancer treatment are also favoring the market growth. Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Treatment Type:

Cytarabine
Anthracycline Drugs
Alkylating Agents
Anti-Metabolites
Tyrosine Kinase Inhibitors
Others

Breakup by Drug Type:

Small Molecule Drugs
Biopharmaceuticals

Breakup by Route of Administration:

Oral
Injectables

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene, Roche Holding AG, Gilead Sciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

How has the global acute myeloid leukemia therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global acute myeloid leukemia therapeutics market?
What are the key regional markets?
What is the breakup of the market based on the treatment type?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global acute myeloid leukemia therapeutics market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Acute Myeloid Leukemia Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Treatment Type

6.1 Cytarabine
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Anthracycline Drugs
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Alkylating Agents
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Anti-Metabolites
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Tyrosine Kinase Inhibitors
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast

7 Market Breakup by Drug Type

7.1 Small Molecule Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Biopharmaceuticals
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Injectables
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Abbvie Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Amgen Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Bristol-Myers Squibb Company
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Celgene
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 SWOT Analysis
- 14.3.5 Roche Holding AG
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
- 14.3.6 Gilead Sciences Inc.
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Novartis AG
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
- 14.3.8 Pfizer Inc.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi S.A.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
- 14.3.10 Takeda Pharmaceutical Company Limited
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis

급성 골수성 백혈병(AML) 치료 시장 보고서 : 치료 유형별, 약물 유형별, 투여 경로별, 지역별(2025-2033년)

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033

본 보고서에서 다루는 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 급성 골수성 백혈병(AML) 치료 시장

제6장 시장 내역 : 치료 유형별

제7장 시장 내역 : 약물 유형별

제8장 시장 내역 : 투여 경로별

제9장 시장 내역 : 지역별

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도